Multi‐Target Drug Design in Alzheimer's Disease Treatment: Emerging Technologies, Advantages, Challenges, and Limitations

PMCID: PMC12175645

PMID: 40531439

DOI: 10.1002/prp2.70131

Journal: Pharmacology research & perspectives

Publication Date: 2025-6-18

Authors: Hossain MS, Hussain MH

Key Points

• Multi-target drug design offers a more holistic approach to treating Alzheimer's disease by simultaneously addressing multiple pathological mechanisms
• Emerging technologies like AI and nanomedicine show promise in improving drug design precision and blood-brain barrier penetration
• Future research must focus on personalized medicine approaches, recognizing the diverse pathological presentations of AD among individuals

Summary

This comprehensive review explores multi-target drug design (MTDD) as a promising therapeutic strategy for Alzheimer's disease (AD), addressing the limitations of traditional single-target pharmaceutical approaches. The research highlights the complex, multifactorial nature of AD, which requires more sophisticated intervention strategies that can simultaneously target multiple pathological pathways, including amyloid-beta accumulation, neurofibrillary tangles, and neuroinflammation.

The review emphasizes the potential of emerging technologies like artificial intelligence, machine learning, and nanomedicine to enhance MTDD precision. By integrating advanced computational methods and innovative drug delivery systems, researchers aim to develop more effective therapeutic interventions that can potentially halt or reverse AD progression. The approach represents a paradigm shift from traditional drug development, offering a more comprehensive and nuanced strategy for managing this complex neurodegenerative disorder.